AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: Result Interpretation Questions for Memory Clinic Patients

Learn what positive, negative, and borderline blood scores mean and which follow-up questions to bring to clinic.

The AAIC 2026 primary-care findings mean a negative PrecivityAD2 blood result, a test for Alzheimer-related proteins, makes Alzheimer pathology much less likely. For memory-clinic patients, a positive result raises concern but does not alone diagnose Alzheimer's and points to confirmatory testing. Lund University researcher Sebastian Palmqvist presented a prospective Swedish study of 1,310 patients and 165 physicians. The Alzheimer's Association reports the presentation took place at AAIC 2026 in London on July 14, 2026.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

What did the blood test measure?

The studied PrecivityAD2 test measured two plasma signals. Amyloid-beta 42/40 is a ratio of protein fragments in blood linked to plaques. Phosphorylated-tau-217 is a modified tau protein linked to Alzheimer changes.

The lab combined them into an Amyloid Probability Score, called APS2, from 0 to 100. Medscape Medical News reports primary-care accuracy rose from about 65% before blood results to 93% after, near specialists at 94% in Medscape Medical News report. The Alzheimer's Association reports physicians changed the diagnosis in about one-third of patients. They also changed planned workup or future care in more than half of cases.

Why does a negative result carry weight?

Investigators found the test was especially helpful for ruling out Alzheimer's disease. A negative result in primary care strongly reduced the likelihood of Alzheimer pathology, according to the Alzheimer's Association overview in Alzheimer's Association overview. Medscape's summary of the Alzheimer's Association 2025 guideline sets a high bar for triage use.

Sensitivity means the share of true Alzheimer cases the test catches. A test needs at least 90% sensitivity for a negative to rule out disease. A positive then still needs confirmation with PET brain imaging or CSF spinal-fluid testing.

What does a positive or middle score mean?

A higher APS2 score means higher estimated likelihood of amyloid pathology, not a definite stage or prognosis. Medscape's summary of the 2025 guideline says a blood test needs at least 90% sensitivity plus 90% specificity to replace PET or CSF. Specificity means the share of people without Alzheimer pathology the test correctly calls negative.

A middle or low-positive score needs clinic context most. The Los Altos Neurology evidence review notes the AAIC 2026 data came from a Swedish conference presentation, not yet peer-reviewed validation. Local rates of disease and lab cutoffs can shift what the same score means for you.

What should you ask at the memory clinic?

Longevity Benchmark summarizing FDA information reports PrecivityAD2 was cleared on Aug. 20, 2026 in Longevity Benchmark summary of FDA information.

It applies only to adults age 40 and older with signs of cognitive impairment being evaluated, not for screening or standalone diagnosis. The Los Altos Neurology evidence review notes predictive value shifts with local prevalence and assay cutoffs. Your clinic may use a different cutoff than the Swedish study.

  • Bring symptom timeline, medicines, sleep and mood changes, and prior scans
  • Ask whether your score rules out Alzheimer pathology or points to PET or CSF confirmation
  • Ask which cutoff your clinic uses and how the result changes your next test, referral, or treatment plan

You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.